Brokers Provide Earnings Forecast for Xeris Biopharma in Q1 2025

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS – Free Report) has recently come under the analytical lens of equities research experts at HC Wainwright. In a report published on March 7, 2025, analyst O. Livnat presented expectations for the company’s first quarter earnings of 2025. Livnat estimates that Xeris Biopharma will report earnings of ($0.08) per share during this quarter.

HC Wainwright currently maintains a “Buy” rating for Xeris Biopharma’s stock, with an optimistic target price set at $8.00. Looking at broader expectations, the consensus estimate for the full-year earnings for the company in 2025 stands at ($0.41) per share. The analysis also provided insights into subsequent quarters, forecasting earnings of ($0.06) EPS for Q2 2025, ($0.01) EPS for Q3 2025, and a possible turnaround in Q4 2025 with an expected $0.01 EPS. For the fiscal year ending in 2029, the earnings estimate is projected at $0.78 EPS.

Other analysts have also weighed in on Xeris Biopharma, suggesting optimism about its future. Craig Hallum recently adjusted their target price upward from $5.00 to $6.50, corresponding with a “Buy” rating declared in their latest report. In a similar vein, Leerink Partners has upped their price target from $5.00 to $6.00, endorsing the stock with an “Outperform” rating. Piper Sandler kept a neutral stance while raising their target price from $3.00 to $4.00. Additionally, Jefferies Financial Group reiterated a “Buy” rating and increased their price target from $4.00 to $6.00 in their previous appraisal.

As of late, one research analyst has given Xeris Biopharma a hold rating, while five analysts have designated it as a Buy. According to MarketBeat, the overall consensus rating for Xeris Biopharma is classified as a “Moderate Buy,” with an average target price pegged around $5.92.

Xeris Biopharma's Current Stock Performance

On the trading floor, Xeris Biopharma (NASDAQ:XERS) opened at $4.59 on Monday. The company’s 50-day moving average price currently stands at $3.59, while its 200-day moving average price is $3.27. Over the past year, the stock has seen a low of $1.69 and a high of $4.61. At present, Xeris Biopharma boasts a market capitalization of approximately $684.28 million, a price-to-earnings ratio of -10.20, and a beta value of 2.32, indicating its volatility in the market.

Institutional Investors' Interest in Xeris Biopharma

Recent trading activity has also piqued the interest of institutional investors, prompting several to adjust their stakes in Xeris Biopharma. Mackenzie Financial Corp increased its investment by a significant 446.0% during the fourth quarter, now holding 129,952 shares of the company valued at $441,000 after acquiring an additional 106,153 shares. Similarly, Squarepoint Ops LLC expanded its position by 118.2%, now owning 40,769 shares worth $138,000 after buying an extra 22,084 shares. Other firms, such as Two Sigma Advisers LP and Stonepine Capital Management LLC, also acquired new stakes in the company. Collectively, hedge funds and institutional investors control about 42.75% of Xeris Biopharma’s shares.

Xeris Biopharma Overview

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company based in Illinois. It focuses on the development and commercialization of innovative therapies. Some of its notable products include Gvoke, a ready-to-use glucagon solution for severe hypoglycemia; Keveyis, a treatment for specific types of periodic paralysis; and Recorlev, a cortisol synthesis inhibitor approved to treat Cushing's syndrome in adults.

earnings, predictions, stocks